血栓通胶囊联合拜阿司匹灵对冠心病患者阿司匹林抵抗的临床治疗效果分析  

作　　者：张珺 

机构地区：[1]西宁市第一人民医院,青海西宁810000

出　　处：《临床医药文献电子杂志》2020年第92期6-7,共2页Electronic Journal of Clinical Medical Literature

摘　　要：冠心病近年来已经成为发病率较高,且发病基础年龄呈现较低趋势的一种疾病类型。进一步分析冠心病的病因,主要是由于人体的冠状动脉发生粥样硬化后导致的血管疾病,当患者的冠状动脉发生粥样硬化,会导致人体的血管出现闭塞或者狭窄的问题。长期持续下去患者的心肌区域会出现缺血或因缺血导致的坏死现象。严重的情况下,可能导致猝死的现象发生[1]。从药物治疗的角度上来讲,可知阿司匹林是可选用的一种典型药物。心脑血管疾病的治疗中,阿司匹林作为经典的非甾体类抗炎药,被临床广泛使用。但这种药物在具体应用时,对于某一部分患者仍然存在不适宜应用的问题。如果在临床治疗中给予阿司匹林用药,会发生缺血性事件,这就是所谓的“阿司匹林抵抗”[2]。在相关的研究结果中,若发生了药物抵抗现象,则冠心病患者病的死亡概率明显增加增加[3]。本文所探讨的血栓通胶囊与拜阿司匹灵联合应用,解决冠心病患者的阿司匹林抵抗问题,检验临床疗效。coronary heart disease has become a disease type with a high incidence and a relatively low incidence rate in recent years.Further analysis of the causes of coronary heart disease,mainly due to the human body's coronary artery atherosclerosis caused by vascular disease,when the patient's coronary artery atherosclerosis,will lead to the human body's vascular occlusion or stenosis.Long term persistence of patients with myocardial ischemia or necrosis caused by ischemia.In severe cases,sudden death may occur.From the perspective of drug treatment,aspirin is a typical drug.Aspirin,as a classic non steroidal anti-inflammatory drug,is widely used in the treatment of cardiovascular and cerebrovascular diseases.However,this drug is not suitable for a certain part of patients.If aspirin is given in clinical treatment,ischemic events will occur,which is called"aspirin resistance".In related research results,if drug resistance occurs,the death probability of patients with coronary heart disease increases significantly.In this paper,Xueshuantong capsule combined with baiaspiling can solve the problem of aspirin resistance in patients with coronary heart disease and test the clinical efficacy.

关 键 词：冠心病 血栓通胶囊 阿司匹林 药物抵抗 

分 类 号：R541.4[医药卫生—心血管疾病]